Gee, you make it sold like the 25Mil shares are sold retail, 100 here, 500 there. It doesn't work that way. Who needs these shares? The hedge funds that shorted 50 million shares- thats who and they will buy a ton at one time via Cowen et al. They are not sitting there buying 100 shares. The offer will probably be over subscribed anyway. Holding your short over the weekend is a huge risk. When shorts start screaming non-sense they are close to walking into the light. Have a nice weekend.
The stock was very over bought, it was due for a pull back and I expected it to go to $46+, but so far it has stayed very strong. It could still drop more next week.
noted this also...Wedbush Cuts Price Target to $66 on Cepheid (CPHD) Following 2Q15
July 24, 2015 10:13 AM EDT Send to a Friend
Wedbush reiterated an Outperform rating on Cepheid (NASDAQ: CPHD), and cut the price target to $66.00 (from $67.00), following 2Q15 ...
I wrote a reply but I guess the yahoo God took it off. Basically it was an fyi . Saw it and thought it was interesting.
Evercore ISI downgraded Cepheid (NASDAQ: CPHD) from Hold to Sell with a price target of $53.50. Analyst Vijay Kumar noted a 42% rally since April and warned slowing growth and Q4 risk could lead to multiple compression.
"Shares of CPHD have rallied ~42% since reporting earnings on 4/23 vs. the S&P 500 at ~12%, largely due to strength in 1Q commercial clinical revenues, optimism around new product pipeline potential and a general benefit from being included in several key biotech indices/ ETFs that have rallied notably (high correlation vs. NBI Biotech Index on a 1 and 2 year basis)," said Kumar.
"Commercial clinical revenue growth slowed in 2Q despite a pull forward of ~$2MM of revenues from 3Q, and sequentially revenues came in flattish, something that was last seen in 2008," continued the analyst. "Furthermore, the 3Q’15 guidance range of ~$125-128 MM came in below Street estimates (~$136 MM), and implies a second straight Q of deceleration in commercial clinical revenue growth. Even adjusting for ~$5MM of HBDC revenues (related to 300 systems order from India) that were pulled from 3Q guidance and $2 MM related to revenue pull forward, the 3Q guidance came in below ST estimates."
"Despite these moving parts, management tweaked up the low end of the revenue guidance (~$2 MM) for FY15 to a range of $544- $553 MM. This implies a sequential 3Q to 4Q step up in revenues in range of $23-$32, which is well above the historical norm and raises uncertainty on the back of recent revenue trend," Kumar added. "We believe that until the 4Q has been derisked, this will likely weigh in on multiples, compressing it from recent highs to more in-line historical averages of ~6x forward revenues and ~11.5x EV/Gross Profits."
For an analyst ratings summary and ratings history on Cepheid click here. For more ratings news on Cepheid click here.
Shares of Cepheid closed at $62.93 yesterday.
You said it...a couple of days...this thing will be over and done with by next week. Shareholders dealing with this like its a non-issue. Go Fish
We think alike, dumped ARRY (failed study), lost a little $, but gained way more back with EXEL / ITCI. How about that !
Remember I retired in 2013, patients were still using Li+, but I did notice patients stopping it and getting other Rx. You have to do levels with Li+.